An observational study in Pregnant Individuals, Obesity & Overweight and Gestational Weight Gain, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by University of Kansas Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Obesity by University of Kansas Medical Center — 9 open to participants now, 9 under way, none of them phase 3. Obesity · University of Kansas Medical Center.
Among the 32 studies in Obesity by University of Kansas Medical Center, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 32nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →9 of the 32 studies in Obesity by University of Kansas Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Kansas Medical Center · Sites in United States
Ages 18–64
University of Kansas Medical Center · Sites in United States
Ages 18–35
University of Kansas Medical Center · Sites in United States
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 60 across the 29 interventional studies, 60 across the 3 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Kansas Medical Center is the lead sponsor of 493 studies on the registry; 111 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
2 of the studies in Obesity by University of Kansas Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06640179University of Kansas Medical CenterFeasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL) | 2027-02-01 |
| NCT05985486University of Kansas Medical CenterBrain Outcomes With Lifestyle Change in Down Syndrome | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Obesity by University of Kansas Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn if using GLP-1RA medications for weight loss before pregnancy influences gestational weight gain and pregnancy outcomes. The main aims of the study are to:
Researchers will compare pregnant women with a history of GLP-1RA use to pregnant women who have not used a GLP-1RA to compare differences.
Participants will be asked to complete questionnaires at multiple timepoints during and after pregnancy that ask questions about medication history, thoughts and feelings around food, etc.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become widely used for the treatment of obesity because they produce substantial weight loss and improve cardiometabolic health. As use of these medications increases among women of reproductive age, more individuals are conceiving after treatment with GLP-1RAs. Because GLP-1RAs are not recommended during pregnancy, therapy is typically discontinued before conception or immediately after pregnancy is recognized. Although weight regain following GLP-1RA discontinuation has been demonstrated in nonpregnant populations, the effects of discontinuation on gestational weight gain and pregnancy outcomes remain poorly understood.
The GROW study is a prospective observational cohort study designed to evaluate the association between preconception GLP-1RA exposure and maternal and neonatal outcomes. Approximately 400 pregnant women aged 18 to 45 years who are at or before 20 weeks of gestation will be enrolled. Participants will be classified according to whether they used a GLP-1RA within the three years prior to conception. This is an observational study, and no investigational treatment or intervention will be provided.
Participants will complete questionnaires at baseline, during late pregnancy (32-36 weeks gestation), 6-10 weeks postpartum, and 6 months postpartum. Information collected will include demographic characteristics, history of GLP-1RA use, food noise, dietary intake (optional), addictive-like eating behaviors, and infant feeding practices. Maternal and neonatal clinical outcomes will be abstracted from the electronic medical record.
The primary objective is to compare gestational weight gain between women with and without preconception GLP-1RA exposure. Secondary objectives are to compare obstetrical outcomes, food noise, and dietary intake between groups. Findings from this study will improve understanding of the effects of GLP-1RA discontinuation before pregnancy and may help inform counseling and clinical management of women who conceive after treatment with these medications.
Pregnant women being seen at The University of Kansas Health System for an initial prenatal visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with a history of GLP-1RA use.
Participants who have never used a GLP-1RA medication.
Gestational weight gain
Total gestational weight gain, calculated from clinical weight measurements recorded in the electronic medical record and compared between participants with preconception GLP-1RA exposure and those without exposure.
Time frame: From the start of pregnancy to delivery.
Plan to share: No — De-identified individual participant data will not be made available to other researchers because data sharing is not included in the study protocol or informed consent.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 24 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kansas Medical Center →